Combined hepatocellular cholangiocarcinoma: A clinicopathological update  

作　　者：Mukul Vij Fadl H Veerankutty Ashwin Rammohan Mohamed Rela 

机构地区：[1]Department of Pathology,Institute of Liver Disease and Transplantation,Chennai 600044,India [2]Comprehensive Liver Care Institute,VPS Lakeshore,Cochin 682040,India [3]Institute of Liver Disease and Transplantation,Dr.Rela Institute and Medical Centre,Chennai 600044,India

出　　处：《World Journal of Hepatology》2024年第5期766-775,共10页世界肝病学杂志（英文版）（电子版）

摘　　要：Combined hepatocellular-cholangiocarcinoma(cHCC-CCA)is a rare primary liver cancer associated with an appalling prognosis.The diagnosis and manage-ment of this entity have been challenging to physicians,radiologists,surgeons,pathologists,and oncologists alike.The diagnostic and prognostic value of biomarkers such as the immunohistochemical expression of nestin,a progenitor cell marker,have been explored recently.With a better understanding of biology and the clinical course of cHCC-CCA,newer treatment modalities like immune checkpoint inhibitors are being tried to improve the survival of patients with this rare disease.In this review,we give an account of the recent developments in the pathology,diagnostic approach,and management of cHCC-CCA.

关 键 词：Combined hepatocellular-cholangiocarcinoma Immunotherapy NESTIN Hepatocellular carcinoma CHOLANGIOCARCINOMA Liver cancer Biomarker Immune checkpoint inhibitors Pathology Genomic landscape 

分 类 号：R735.7[医药卫生—肿瘤]